CDX.AX - CardieX Limited
| Previous close | 0.1850 |
| Open | 0.1800 |
| Bid | 0.2100 x 281200 |
| Ask | 0.2050 x 14158300 |
| Day's range | 0.1800 - 0.2050 |
| 52-week range | 0.1800 - 0.4900 |
| Volume | |
| Avg. volume | 155,778 |
| Market cap | 29.411M |
| Beta (5Y monthly) | 1.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1300 |
| Earnings date | 29 Aug 2023 - 04 Sept 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireATCOR Launches New 2,000-Patient Longitudinal Retrospective Study for Heart Health
ATCOR Medical, a subsidiary of CardieX and developer of innovative medical devices and digital health solutions to optimize hypertension management and improve clinical trial patient outcomes, today announced it has launched a single-center retrospective study of 2,000 hypertensive patients to identify associated care outcomes resulting from the routine monitoring of central aortic blood pressure (cBP) and peripheral blood pressure (pBP). With over six years of patient data, this longitudinal st
PR NewswireCardieX Receives FDA 510(K) Clearance for a World-First Vascular Biometric Monitor - the CONNEQT Pulse
CardieX Limited (ASX: CDX) (CardieX, the Company), today announced its new arterial health monitor, the CONNEQT Pulse (Pulse), has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). Pulse is the only vital signs monitor targeted at home, clinician, and clinical trial use that provides measurements of both brachial blood pressure (the pressure at your arm) and central blood pressure (the pressure at your aorta/heart) in addition to multiple other vascular health biomarker
PR NewswireCardieX advances to final phase of NIH's inaugural RADx Tech for Maternal Health Challenge
Global health technology company, CardieX Limited, is pleased to announce it has advanced to the final phase of the National Institutes of Health's (NIH) RADx Tech for Maternal Health Challenge, receiving a $75,000 cash prize.
- PR Newswire
CardieX Subsidiary ATCOR Partners with Power to Advance Patient Recruitment Diversity and Increase Patient Access in Clinical Trials
CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes, today announced a partnership between its ATCOR subsidiary and Power, a fast growing patient recruitment marketplace democratizing access to clinical trials for all patients.
PR NewswireCardieX Subsidiary ATCOR Partners with Invaryant to Enable Clinical Trials with Advanced New AI Medical Technology
CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes, today announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to improve quality, equity and safety, and provides comprehensive, integrated, high quality data to accelerate research and innovation.
PR NewswireCardieX Announces CONNEQT Pulse, the World's First Customizable Dual Blood Pressure and Arterial Health Monitor
CardieX Limited (ASX: CDX), a global health technology company focused on cardiovascular disease, has together with its manufacturing partner Andon filed a 510(k) premarket submission with the U.S. Food and Drug Administration (FDA) for the CONNEQT Pulse (Pulse) – a world first dual blood pressure and arterial health monitor targeted at the home health, remote patient monitoring, and decentralized clinical trial markets.